Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Arabian Drilling Co
SAU:2381
|
SA |
|
Best Buy Co Inc
NYSE:BBY
|
US |
Cyclacel Pharmaceuticals Inc
Stock-Based Compensation
Cyclacel Pharmaceuticals Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$955m
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$894m
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
$494m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$685.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
$993.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
Cyclacel Pharmaceuticals Inc
Glance View
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.
